MUSK and myasthenia gravis: Given the well-documented challenges in managing MuSK+ MG patients and the inefficacy of complement-targeted therapies, the authors advocate for the consideration of RTX as a first-line therapy in this population (Vakrakou et al., 2023; Table 1).